March 19, 2021
Read 1 min
Source / Publications
The authors report that there is no relevant financial information.
Patients who had previously been infected with COVID-19 were approximately 85% more likely to develop a symbolic reassignment and 80% more likely to develop a general relapse over the next 8 months, according to patients. research.
“Right now, and in the future, there is a shortage of COVID-19 vaccines in the world. Despite this, we have been vaccinating inadvertent people who already have COVID-19, ” Michael B. Rothberg, MD, MPH, vice chair for research at Cleveland Institute of Clinical Medicine and professor of medicine at Case Western Reserve University, with Healio. “One reason for this is that officials have been reluctant to say that the disease has been on the rise for more than a few months. We had a database of 150,000 patients tested for COVID-19 – both positive and negative. We realized that if we followed these patients over time, we would see how many patients who passed would be tested for COVID-19 in the future. “
The patients in the study were tested for COVID-19 by PCR starting March 12, 2020, through February 24, 2021. The main outcome was recurrence, which was defined as 90 days or more of infection. after the first test.
The results of the study, published in Clinical infectious diseases, showing that 8,845 (5.9%) of the patients were tested positive and 141,480 (94.1%) tested negative by August 30, 2020. According to the researchers, 1,278 (14.4%) of the patients were tested positive. advanced patients re-diagnosed after 90 days, with 62 with possible re-diagnosis. Of these patients, 31 (50%) were symptomatic. Among patients with an initial negative test, the study showed that 5,449 (3.9%) were subsequently positive and 3,191 (58.5%) of these were symbolic.
Michael B. Rothberg
The researchers found that preexisting disease offered 81.8% (95% CI, 76.6–85.8) protection against overall relapse and 84.5% (95% CI, 77.9–89.1) protection against relapse. symbolic regression. Rothberg said this protection increased over time, exceeding 90% between 5 and 8 months.
“Patients who have undergone COVID-19 enrollment appear to be generally protected from relapse for at least 8 months,” Rothberg said. “Vaccine circulation plans should be considered in short supply. ”